Sfoglia per AUTORE
STILGENBAUER S
Collezione AOU Città della Salute di Torino

  

Items : 6

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL. in HemaSphere / Hemasphere. 2024 Sep 17;8(9):e70004. doi: 10.1002/hem3.70004. eCollection 2024 Sep.

2024
AOU Città della Salute di Torino
AOU Novara

Popov VM; Pangalis GA; Espinet B; Bosch F; Sportoletti P; Panagiotidis P; Gozzetti A; Oscier D; Zuchnicka J; Yassin M; Yañez L; Yagci M; Xu Z; Walewska R; Vukovic V; Vrachiolias G; Vitale C; Visentin A; Vassilakopoulos T; Tse E; Tomic K; Tadmor T; Stilgenbauer S; Soliman DSA; Smirnova S; Simkovic M; Shokralla T; Shen Y; Schiwitza A; et alii...

The EHA Research Roadmap: Malignant Lymphoid Diseases. in HemaSphere / Hemasphere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eCollection 2022 Jun.

2022
AOU Città della Salute di Torino

Dreyling M; André M; Gökbuget N; Tilly H; Jerkeman M; Gribben J; Ferreri A; Morel P; Stilgenbauer S; Fox C; Maria Ribera J; Zweegman S; Aurer I; Bödör C; Burkhardt B; Buske C; Dollores Caballero M; Campo E; Chapuy B; Davies A; de Leval L; Doorduijn J; Federico M; Gaulard P; Gay F; Ghia P; Grønbæk K; Goldschmidt H; Kersten MJ; et alii...

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. in Leukemia / Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.

2022
AOU Alessandria
AOU Città della Salute di Torino

Deckert M; Ponzoni M; Pennese E; Cabras G; Thurner L; Smith J; Rummel M; Hertenstein B; Schmoll HJ; Krause SW; Zanni M; Pisani F; Orsucci L; Tucci A; Panse J; Stilgenbauer S; Hess G; Keller U; Balzarotti M; Pukrop T; Gørløv JS; Linton KM; Johnson PW; Hemmaway C; Roth A; Krampera M; Ilariucci F; Fabbri A; Binder M; et alii...

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. in Blood / Blood. 2021 Apr 22;137(16):2267-2271. doi: 10.1182/blood.2020008609.

2021
AOU Città della Salute di Torino

Fürstenau M; Fink AM; Schilhabel A; Weiss J; Robrecht S; Eckert R; de la Serna J; Crespo M; Coscia M; Vitale C; Böttcher S; Weppner G; Ritgen M; Stilgenbauer S; Tausch E; Fischer K; Hallek M; Eichhorst B; Brüggemann M; Herling CD;

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.

2017
AOU Città della Salute di Torino

Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; et alii...

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.

2016
AOU Città della Salute di Torino

Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; et alii...